#liquid biopsy testing

[foundationmedicineroche]

FoundationOne®Liquid, our liquid biopsy test, opens up the opportunity of comprehensive genomic profiling for more solid tumour patients

When Tissue Biopsy is not feasible, try FoundationOne®Liquid - Liquid Biopsy Test. It opens up the opportunity of comprehensive genomic profiling for solid tumour patients.

Our FDA-approved liquid biopsy comprehensive genomic profiling service offers a minimally-invasive option, alternative or complementary to FoundationOne CDx, for all patients with solid tumours at optimal times beneficial to their treatment journey.

FoundationOne Liquid CDx reports 300 genes and is able to detect both novel and known variants, including four classes of genomic alterations (base substitutions, insertions or deletions, copy number alterations and gene rearrangements), genomic signatures and Tumour Fraction, to provide prognostic, diagnostic and predictive insights that inform research or treatment decisions for individual patients across all solid tumours.

[foundationmedicineroche]

Liquid Biopsy Test

Molecular Testing and Molecular Insights leader Foundation Medicine provides powerful insights to help personalise treatment strategies. Contact for Foundationone Testing.

As part of our long-standing commitment to pioneering progress in precision medicine, molecular insights leader Foundation Medicine has become a member of the Roche Group. Together Roche and Foundation Medicine are bringing comprehensive genomic profiling to cancer patients around the world, combining Roche’s expertise and commitment in oncology and Foundation Medicine’s leading technology, validation and experience in cancer profiling.

Comprehensive genomic profiling is a tumour testing method that utilizes next generation sequencing technology to identify all four classes of alterations across a large set of cancer-related genes (>50) known to drive cancer across tumour types.